Answers are grounded in this paper and cite their sources.
Data S1. Methods. Figure S1. Graphic representation of the expression levels of PI3K/AKT/mTOR and MAPK pathways effectors in cutaneous melanomas and nevi. Table S1. Clinico-pathological features of cutaneous melanomas. Table S2. Description of the antibodies used. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Pópulo et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: